QPPV.COM KNOWLEDGE ASSESSMENT

Golimumab Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Golimumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which interpretation of new dyspnoea and oedema in a patient receiving golimumab is most appropriate?

Evaluate possible heart failure while also assessing infection, anaemia, renal disease and other competing causes Assume the symptoms confirm a golimumab-related heart-failure event Exclude heart failure because TNF inhibitors affect only immune-mediated disease Code the event as pulmonary tuberculosis without further assessment

Question 2 of 10 Which set of variables is most important when reconstructing a golimumab exposure for a reported serious infection?

Indication, route, recent dose, infection characteristics and concomitant immunosuppression Only the patient's age and the date of the first prescription The product's international nonproprietary name without presentation or administration details The spontaneous-report count for all anti-TNF medicines

Question 3 of 10 Why should ulcerative-colitis and rheumatoid-arthritis populations generally not be pooled without adjustment in an infection analysis?

Their disease severity, corticosteroid exposure, hospitalisation, nutritional status and baseline infection risks may differ Golimumab has a different molecular target in ulcerative colitis Rheumatoid arthritis patients cannot experience serious infections during anti-TNF treatment Pooling is prohibited because the diseases are treated in different medical specialties

Question 4 of 10 What best explains the central pharmacovigilance trade-off associated with TNF blockade?

The pathway contributes to inflammation but also supports granuloma maintenance and defence against intracellular pathogens TNF blockade directly causes all bacterial infections regardless of disease or treatment context TNF is required only for mucosal inflammation and has no role in systemic host defence Blocking TNF selectively suppresses pathological inflammation without affecting physiological immunity

Question 5 of 10 Which description best captures golimumab's pharmacological classification?

A fully human IgG1 kappa monoclonal antibody that neutralises TNF-alpha A soluble TNF-receptor fusion protein that removes TNF from circulation A small-molecule inhibitor that blocks intracellular TNF synthesis A chimeric antibody that selectively depletes TNF-producing lymphocytes

Question 6 of 10 A patient develops neutropenia while receiving golimumab and methotrexate. Which follow-up approach is most appropriate?

Review serial blood counts, concomitant medicines, infection and recovery after treatment interruption Attribute the neutropenia exclusively to golimumab based on the event term Discard the case because cytopenias cannot occur during immune-modifying treatment Assess only the patient's most recent golimumab dose date

Question 7 of 10 An inspector reviews an organisation's golimumab pharmacovigilance system. Which capability would most directly demonstrate effective translation of class knowledge into product-level surveillance?

The ability to retrieve and medically assess cases using indication, route, baseline TB or HBV status and concomitant immunosuppression A database search that identifies only the term 'anti-TNF' without patient or product details A policy stating that all class signals automatically apply with identical severity to golimumab A process that excludes cases lacking a confirmed causal relationship at initial receipt

Question 8 of 10 Which approach best supports periodic benefit-risk evaluation of golimumab?

Integrate disease-control benefits with safety evidence while separating established class risks from new product-specific findings Focus only on the number of serious adverse-event reports regardless of exposure or indication Treat all anti-TNF products as having identical risks and pool their data without qualification Evaluate safety independently of route, age, indication and concomitant immunosuppression

Question 9 of 10 Which finding would provide the strongest support for a suspected demyelinating event associated with golimumab?

A compatible neurological syndrome supported by MRI or other specialist evaluation Transient nonspecific paraesthesia with no examination or imaging findings A positive tuberculosis screening test An isolated increase in liver transaminases

Question 10 of 10 Why must jurisdiction and route be retained in golimumab exposure records?

Authorised routes and indication sets can differ between regions, and subcutaneous and intravenous use create different exposure contexts The international nonproprietary name is insufficient because golimumab changes into a different molecule by country Route is relevant only for product distribution and not for pharmacovigilance Jurisdiction matters only for spontaneous-report submission deadlines

Golimumab Classification, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings